Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma
Trial Parameters
Brief Summary
To find the recommended dose of NY-ESO-1 TCR/IL-15 NK cells that can be given to patients with relapsed or refractory MM. To learn if the dose of NY-ESO-1 TCR/IL-15 NK cells found in Part A can help to control the disease.
Eligibility Criteria
Inclusion criteria: 1. Patients with multiple myeloma with an expression of NY-ESO-1 by immunohistochemistry in the pre-enrollment tumor sample 2. Patients are HLA-A\*02:01positive on HLA typing 3. Patients with relapsed or refractory MM (patients with solitary plasmacytoma are not eligible) who meet the following criteria: 1. \> or = 4 prior lines of therapy (including exposure to at least one proteasome inhibitor, ImiD, and anti-cd38 antibody and bcma targeted agent 2. have measurable disease (serum monoclonal (M) protein level ≥0.5 g/dL, and/or urine M protein level ≥200 mg/day, and/or involved serum FLC level ≥10 mg/dL provided the serum-free light-chain ratio is abnormal \*refractory is defined as a documented progressive disease during or within 60 days \[measured from the last dose of any drug within the regimen\] of completing treatment with the last anti-myeloma regimen before study entry. 4. Patients with relapsed or refractory plasma cell leukemia who have received at least